Real‐world assessment of acute red cell exchange for stroke in sickle cell disease
- 25 May 2025
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 207 (1) , 217-224
Abstract
Summary: Cerebrovascular accidents (CVA) are one of the most devastating complications in sickle cell disease (SCD). Chronic transfusion therapy has been established for primary and secondary prevention of CVA in SCD, resulting in a notable reduction in CVA incidence. For individuals with SCD presenting with CVA, the impact of acute management on neurological outcomes is not well studied. Herein, we examine the neurological outcomes of 29 children and adults with SCD who received acute red cell exchange (RCE) as primary therapy for neurological events at a single institution. Twelve (41%) individuals had a prior history of CVA, and 12 (41%) were on chronic transfusions. Among 13 adults, 3 (23%) had a history of diabetes and 4 (31%) had a history of hypertension. One adult (7.7%) received thrombolytic therapy; the remainder were ineligible due to age, timing of presentation, intracranial haemorrhage or transient symptoms. Higher post‐RCE haematocrit was associated with decreased odds of death or persistent neurological symptoms at hospital discharge (OR 0.69, 95% CI: 0.45–0.94, p = 0.017). Optimal acute management of adults living with SCD presenting with CVA remains an understudied yet important topic. Future prospective studies may determine how best to tailor acute management to improve neurological outcomes.Keywords
This publication has 18 references indexed in Scilit:
- Restrictive vs Liberal Transfusion Strategy in Patients With Acute Brain InjuryJAMA, 2024
- Incidence and Risk Factors for New and Recurrent Infarcts in Adults With Sickle Cell DiseaseJournal of the American Heart Association, 2024
- Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke AssociationStroke, 2019
- Genetic, laboratory and clinical risk factors in the development of overt ischemic stroke in children with sickle cell diseaseHematology, Transfusion and Cell Therapy, 2018
- Determinants of resting cerebral blood flow in sickle cell diseaseAmerican Journal of Hematology, 2016
- Hemodynamic Etiology of Elevated Flow Velocity and Stroke in Sickle-Cell DiseaseJournal of Cerebral Blood Flow & Metabolism, 2009
- Discontinuing Prophylactic Transfusions Used to Prevent Stroke in Sickle Cell DiseaseNew England Journal of Medicine, 2005
- Effects of Tissue Plasminogen Activator for Acute Ischemic Stroke at One YearNew England Journal of Medicine, 1999
- Prevention of a First Stroke by Transfusions in Children with Sickle Cell Anemia and Abnormal Results on Transcranial Doppler UltrasonographyNew England Journal of Medicine, 1998
- Tissue Plasminogen Activator for Acute Ischemic StrokeNew England Journal of Medicine, 1995